The book, “Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives“ intends to cover the latest guidelines issued by the US FDA, AASLD/IDSA (American Association For The Study Of Liver Diseases/Infectious Diseases Society of America), ECDC (European Center for Disease Prevention and Control), and NYSDOH-AI (New York State Department of Health Aids Institute)) on HCV screening, diagnosis, treatment and management for the clinicians, physicians, infectious disease experts, and primary care providers (nurses and paramedics).
The contents of the book, “Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives“ not only provide ABC of HCV infection, diagnostic tools, and treatment strategies to common and interested readers but also address current information about some pretty mind-boggling aspects of hepatitis C biology, immunology, pharmacology, therapeutics, and vaccinology to obtain relevant answers with thoughtful explanations of some outstanding problems in the field nowadays.
The book, “Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives“ also covers up-to-date guidelines about patient screening, treatment protocols, and optimization of therapy in real-world clinical settings. The book also summarizes unanswered questions currently faced by investigators in the intriguing molecular pathogenesis of CHC in humans, and physicians, clinicians, hepatologists, and health care officials are concerned with HCV clinical diagnosis and therapeutics. This book would also be a valuable addition to hepatology for curious undergraduate and postgraduate students pursuing a new career in HCV medicine.
About the authors:
Prof. Imran Shahid earned his bachelor's in Science and Pharmacy from the Islamia University of Bahawalpur, Bahawalpur, Pakistan with distinction. He completed his M.Phil and Doctoral degree in Molecular Biology from the National Center of Excellence in Molecular Biology, University of Punjab, Lahore, Pakistan, while working on anti-mRNA-based treatment strategies against hepatitis C infection. He joined the College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia in 2012 and was involved as a lead scientist in two national projects on hepatitis C pathogenesis and breast cancer treatment, respectively. Currently, he is working as an assistant professor at the Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia, where his research is focused on broad areas of virus-host networks in HCV disease progression and their therapeutic interventions. He has published many research and review articles in peer-reviewed international journals and is an active member of the editorial board of several international journals.
Prof. Qaiser Jabeen graduated in Pharmacy from the Islamia University of Bahawalpur, Bahawalpur, Pakistan in 1995. She started her professional career as a Lecturer in 1996 in the parent institution. She completed her M.Phil. and Ph.D. in Pharmacology from the University of Karachi, Pakistan, while working as an active member of the natural products Pharmacology group at the Aga Khan University, Karachi, Pakistan. She served IUB as an Assistant Professor and was followed by an associate Professor for seven years each. Currently, she is working as a Professor and Chairperson of the Department of Pharmacology, Faculty of Pharmacy, the Islamia University of Bahawalpur. She has attended many national and international conferences and seminars and is working as an active member of several committees at the university level. She has a good number of publications of international repute and book chapters to her credit. She is also an active editorial member of various national and international journals
Keywords:
HCV-host interactions, Resistance associated substitutions, Viral Kinetics, HCV vaccinology, HCV immunopathogenesis, HCV treatment guidelines, HCV cell communication, Harder-to-treat populations, HCV diagnostic algorithms, Treatment failure, HCV linkage to care, Real-world challenges, HCV Therapeutics, HCV micro-elimination, Direct-acting antivirals, HCV macro-elimination, HCV diagnostic burnout, Cascade of care, HCV genotypes/subtypes, Universal health coverage
For more information please visit: http://bit.ly/3leFAXs